AGMB — AgomAb Therapeutics N.V. American Depositary Shares
$9.05-2.27%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for AGMB in the TickerWise workspace.
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: BE
- Exchange: NASDAQ
- Employees: 57
- Website: https://agomab.com
Latest SEC filings for AGMB
Latest AGMB news
- AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript Read article
- Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial Read article
- Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.